IDEXX Labs (IDXX) Tops Q2 EPS by 19c; raises outlook

IDEXX Labs (NASDAQ: IDXX) reported Q2 EPS of $2.67, $0.19 better than the analyst estimate of $2.48. Revenue for the quarter came in at $944 million versus the consensus estimate of $934.77 million.

GUIDANCE:

IDEXX Labs sees FY2023 EPS of $9.64-$9.90, versus the consensus of $9.69. IDEXX Labs sees FY2023 revenue of $3.66-3.715 billion, versus the consensus of $3.67 billion.

For earnings history and earnings-related data on IDEXX Labs (IDXX) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Profound Medical names Richard Fabian as president
• Marvell Technology (MRVL) Tops Q2 EPS by 1c, Offers Guidance